LINACS
LINACS Home
OligoCare
Group

CSFR1 targeting TKI

The data below refer to patients treated with CSFR1 targeting TKI as the sole drug class, excluding any concurrent use of drugs from other groups.
Individual Drugs

Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.

Vimseltinib
No data